Bullish releases October 2025 monthly metrics Share CAYMAN ISLANDS--(BUSINESS WIRE)--Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for October 2025 on Thursday, November 6, 2025. These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthl ...

Nov 6, 2025 6:45 AM Eastern Standard Time CHIMERA INVESTMENT CORPORATION REPORTS 3RD QUARTER 2025 EARNINGS Share Q3 2025 Investor Presentation NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: "The third quarter marked an important transition in the history of our business as we moved to cash in preparation for the acquisition of HomeXpress†said Phillip Kardis II, ...

Accessibility StatementSkip Navigation The company is on track to deliver full year results near the low end of its existing guidance ranges WOKING, England, Nov. 6, 2025 /PRNewswire/ -- Nomad Foods Limited (NYSE: NOMD), today reported financial results for the three and nine month periods ended September 30, 2025. Key operating metrics and financial performance for the third quarter 2025, when compared to the third quarter 2024, include: Management Comments Stéfan Descheemaeker, Nomad Foods' Chief Execu ...

Accessibility StatementSkip Navigation Transitions to a more advantageous reserve area at the West Elk mine Returns $24.6 million to stockholders via share buybacks and quarterly dividends; $218.3 million returned to stockholders since the capital return program's launch in February Generates net cash provided by operating activities of $87.9 million and free cash flow of $38.9 million Increases cash and cash equivalents by $31.5 million and overall liquidity by $47.5 million "During Q3, the Core team exec ...

Nov 6, 2025 6:45 AM Eastern Standard Time Warby Parker Announces Third Quarter 2025 Results Share Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) ("Warby Parker†or the "Company†), a direct-to- consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we adv ...

Raises Full-Year Guidance Amid Margin Expansion and Strategic Execution AUSTIN, TX / ACCESS Newswire / November 6, 2025 / Thermon Group Holdings, Inc. (NYSE:THR) ("Thermon" or the "Company"), a diversified industrial technology company and a global leader in industrial process heating solutions, today announced consolidated results for the second quarter ("Q2 2026") of the fiscal year ending March 31, 2026 ("Fiscal 2026"). SECOND QUARTER 2026 HIGHLIGHTS (all comparisons versus the prior year period unless o ...

NEW YORK, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company") today announced financial results for the third quarter ended September 30, 2025. Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: "We are pleased with our third quarter results that reflect investments in sales and marketing, continued progress in our executional capabilities and the early results of our latest new product introductions. We are reaffirming our annual guidance an ...

核心观点 - 礼来公司宣布其研究性每周一次给药的选择性胰淀素受体激动剂eloralintide在治疗肥胖的2期临床试验中取得积极结果，所有剂量组均达到主要终点，体重减轻效果显著优于安慰剂[1] - 基于2期试验的鼓舞性结果，公司计划于今年年底开始该药物治疗肥胖的3期临床研究患者入组[6] - Eloralintide展现出作为胰高血糖素样肽-1疗法替代方案或补充治疗选项的潜力，可能提供强效疗效并改善耐受性[5] 临床试验结果 - 在48周时，所有eloralintide治疗组均达到主要终点，与安慰剂的平均体重减轻0.4%相比，显示出从9.5%到20.1%的优越平均体重减轻[1] - 具体剂量组体重减轻百分比：1 mg组-9.5%（-10.2 kg），3 mg组-12.4%（-13.3 kg），6 mg组-17.6%（-18.7 kg），9 mg组-20.1%（-21.3 kg）[3] - 剂量递增组也显示出显著效果：6/9 mg组-19.9%（-21.0 kg），3/6/9 mg组-16.4%（-17.8 kg）[3] - 试验参与者的平均基线体重为109.1公斤（240.5磅）[3] 药物安全性与耐受性 - 最常见的不良事件为轻度至中度胃肠道症状和疲劳，在较高剂量组中更为常见[4] - 较慢的剂量递增可降低这些不良事件的发生率，1 mg和3 mg组的不良事件发生率与安慰剂相似[4] 药物机制与开发计划 - Eloralintide是一种研究性每周一次给药的选择性胰淀素受体激动剂，可能通过影响饱腹感来减少热量摄入[7] - 公司计划启动eloralintide作为肥胖单药治疗的3期临床研究，并评估其作为胰高血糖素样肽-1疗法补充治疗的用途[6] - 公司还在进行一项2期研究，评估eloralintide单独使用或与tirzepatide联合用于肥胖或超重且患有2型糖尿病的成年人的体重管理[7] 行业意义与战略定位 - 礼来公司正在推进最全面的肥胖药物研发管线，致力于提供反映肥胖患者不同需求和偏好的创新疗法[5] - 公司认为分子特异性在这一类药物中很重要，eloralintide作为选择性胰淀素受体激动剂具有独特作用机制[5] - 该药物数据表明其可能为需要更高效力的患者提供补充选择，扩展肥胖治疗策略[5]

Nov 6, 2025 6:45 AM Eastern Standard Time Tapestry, Inc. Reports Fiscal 2026 First Quarter Results and Raises Full Year Outlook Share Achieved Record First Quarter Revenue and EPS with Growth Exceeding Expectations Link to Download Tapestry's Q1 Earnings Presentation, Including Brand Highlights NEW YORK--(BUSINESS WIRE)--Tapestry, Inc. (NYSE: TPR), a house of iconic accessories and lifestyle brands, today reported results for the fiscal first quarter ended September 27, 2025. Joanne Crevoiserat, Chief Execu ...

Accessibility StatementSkip Navigation THE WOODLANDS, Texas, Nov. 6, 2025 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically-integrated modular accommodations and value-added hospitality services, today reported results for the three months ended September 30, 2025. Financial Highlights for the Third Quarter 2025 2025 Operational Achievements Target has announced over $455 million in multi-year contr ...